Skip to main content
NKGNOTCinactive

NKGen Biotech, Inc.

Biopharma developer (SEC filing verified)·Phase 2·Santa Ana, CA, United States·CEO: Dr. Paul Y. Song M.D.
OncologyNeurology

NKGN evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for NKGN—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

3.2/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

$7.8M

Cash Runway

0.8 mo

Next Catalyst

Financial data as of Mar 31, 2025.

Tracking 2 pipeline candidates · 2 clinical trials for NKGen Biotech, Inc..

Run NKGen Biotech, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available NKGen Biotech, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway0.2

0.8 months

Financial Health2.0

OCF -$3M · Net income $15M

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Pipeline

Regulatory

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

1

Total value held

$193K

HolderSharesValue
meteora capital, llc2,755,935$193K

Short Interest

as of May 21, 2026
% of float
5.5%
Days to cover
0.4
Shares short
1,506,310
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

NKGN short interest

Governance

Frequently asked questions

What is NKGen Biotech, Inc.'s lead drug candidate?

NKGen Biotech, Inc.'s most advanced tracked candidate is snk01 (Phase 1/Phase 2) for Moderate Alzheimer Disease; Alzheimer Disease.

Who is the CEO of NKGen Biotech, Inc.?

Dr. Paul Y. Song M.D. is the chief executive officer of NKGen Biotech, Inc. (NKGN).

Where is NKGen Biotech, Inc. headquartered?

NKGen Biotech, Inc. (NKGN) is headquartered in Santa Ana, CA, United States.

What therapeutic areas does NKGen Biotech, Inc. focus on?

NKGen Biotech, Inc. develops therapies across Oncology, Neurology.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.